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AbstrAct
Objectives We aimed to evaluate the mechanical properties 
and healing patterns 6 and 9 months after implantation of the 
sirolimus-eluting Fantom bioresorbable scaffold (BRS).
Background The Fantom BRS (Reva Medical, San Diego, 
USA) has differentiating properties including radiopacity, 
strut thickness of 125 µm, high expansion capacity and 
has demonstrated favourable mid-term clinical and 
angiographic outcomes.
Methods and results FANTOM II was a prospective, 
single arm study with implantation of the Fantom BRS 
in 240 patients with stable angina pectoris. Guidance by 
optical coherence tomography (OCT) was encouraged and 
was repeated at 6-month (cohort A) or 9-month follow-up 
(cohort B). Matched baseline and follow-up OCT recordings 
were available in 152 patients. In-scaffold mean lumen 
area in cohort A was 6.8±1.7 mm2 and 5.7±1.4 mm2 
at baseline and follow-up (p<0.0001) and was 
7.2±1.6 mm2 and 5.6±1.4 mm2 in cohort B (p<0.0001). 
Mean scaffold area remained stable from 7.1±1.5 mm2 
at baseline to 7.2±1.4 mm2 at 6 months (p=0.12), and 
from 7.4±1.5 mm2 to 7.3±1.4 mm2 at 9 months. Strut 
malapposition was median 0.8 (IQR 0.0;3.5)% and 1.8 (IQR 
0.3;6.0)% at baseline and was 0.0 (IQR 0.0;0.0)% in both 
groups at 6-month and 9-month follow-up. Strut tissue 
coverage was 98.1 (IQR 95.9;99.4)% at 6 months and 
98.9 (IQR 98.3;100.0)% at 9 months.
Conclusions The novel Fantom BRS had favourable 
healing patterns at 6-month and 9-month follow-up as 
malapposition was effectively resolved and strut coverage 
was almost complete. The scaffold remained stable 
through follow-up with no signs of systematic late recoil.
IntrOduCtIOn
Fully bioresorbable scaffolds (BRS) are aimed 
at reducing the long-term risk associated with 
permanent stent implants. Clinical trials of 
the first clinically available BRS have indi-
cated increased rates of early and late scaf-
fold failure compared with newer generation 
permanent drug-eluting stents (DES).1–3 BRS 
failures have been explained by suboptimal 
implantation results4 5 but factors related to 
Key questions
What is already known about this subject?
 ► Bioresorbable scaffolds (BRS) theoretically reduce 
the long-term risks associated with permanent 
drug-eluting stents (DES). However, first generation 
BRS had several mechanical limitations and have 
shown inferior clinical outcome compared to the 
latest generation DES. The novel Fantom BRS has 
demonstrated excellent mid-term clinical and an-
giographic outcome.
What does this study add?
 ► The Fantom BRS was designed to reduce limitations 
associated with first-generation BRS by applying a 
unique radiopaque backbone polymer that allows for 
reduced strut thickness and crossing profile while 
improving expansion capacity. Matched meticulous 
optical coherence tomography analysis revealed fa-
vourable mechanical performance and healing pat-
terns of the scaffold after 6 and 9 months.
How might this impact on clinical practice?
 ► Longer term clinical follow-up in the FANTOM II 
study is ongoing and healing patterns are evaluated 
after 24 and 48 months. Studies in more complex 
lesion subsets are in progress and a randomised 
clinical outcome trial comparing the Fantom BRS 
with best in class permanent DES is in preparation.
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design and properties of the first BRS, Absorb (Abbott, 
USA) may have contributed negatively even in cases with 
optimal implantation results. Absorb BRS had thicker 
struts, a more dense footprint, a larger crossing profile 
compared with latest generation permanent DES.6 Acute 
recoil was larger due to the lower radial strength and the 
limited expansion capacity increased the risk of fractures 
if expanded beyond narrow limits.6 7
Next generation BRS were designed to address these 
issues for improving clinical feasibility and safety. The 
novel sirolimus-eluting Fantom BRS (REVA Medical, 
San Diego, USA) has a desaminotyrosine (DAT) based 
backbone polymer to improve strength and elasticity that 
allows for reduced strut thickness and larger expansion 
beyond the nominal diameter compared with Absorb 
BRS. The polymer of the Fantom BRS contains covalently 
bound iodine making the scaffold radiopaque, thus 
allowing for direct verification of implantation results 
which may further improve feasibility and safety.
The FANTOM II study aimed to investigate safety and 
performance of the Fantom BRS in a multicentre setting. 
The mid-term clinical and angiographic follow-up was 
reported previously and indicated an excellent safety 
profile.8 Here, we report the mechanical performance 
and healing patterns of the Fantom BRS after 6 and 9 
months assessed by baseline adjusted, fully matched 
optical coherence tomography (OCT).
MetHOds
study population
The FANTOM II study was a prospective single-arm, 
multicentre study assessing clinical and angiographic 
outcomes after implantation of the Fantom BRS in 
patients ≥18 years with de novo lesions and evidence of 
myocardial ischemia (stable or unstable angina, postin-
farct angina or silent ischemia). Stenosis severity had 
to be ≥50% and <100% in native coronary vessels with 
Thrombolysis in Myocardial Infarction (TIMI) flow ≥2, 
a reference diameter between 2.5 and 3.5 mm, and a 
lesion length ≤20 mm by visual assessment. Major exclu-
sion criteria were clinical symptoms concordant with 
acute myocardial infarction (AMI), left main stenosis 
≥50%, ejection fraction <40%, need for more than 
one Fantom BRS to cover the lesion, a side branch 
diameter >1.5 mm, moderate to severe calcification 
and significant stenosis ≥50% proximal or distal to 
the target lesion. The study was approved by local or 
national medical ethics committees and health authori-
ties as required. All patients provided written informed 
consent before enrolment.  Clinicaltrials. gov identifier: 
NCT02539966.
OCt study population
Patients were eligible for the OCT substudy population 
if final post-PCI OCT scan and a 6-month or 9-month 
follow-up OCT scan were available in analysable quality.
study device
The Fantom BRS is a sirolimus eluting scaffold with a desa-
minotyrosine (DAT) based backbone polymer. Iodine is 
covalently bound in the polymer to make it radiopaque. 
Strut thickness is 125 µm and the in-phase sinusoidal rings 
are linked by three connectors. Sirolimus is incorporated 
into a polymeric matrix and added to the abluminal side of 
struts with more than 60% of the sirolimus released within 
30 days. Fantom maintains structural integrity and almost 
full radial strength for 3–4 months followed by gradual 
degradation with >60% molecular weight loss within 12 
months and complete bioabsorption within 3–4 years. 
Deliverability is facilitated by a 1.3 mm crossing profile and 
uninterrupted device inflation was allowed. The specified 
postdilatation threshold was 0.5 mm above nominal scaf-
fold diameter but the expansion capacity was by in vitro 
testing shown to exceed 1.0 mm above the nominal size 
(vendor information). The Fantom BRS was available in 2.5 
mm and 3.0 mm versions during the study.
study procedure
The treatment protocol has been published8 and was as 
follows (shortened): (1) predilatation of the lesion with 
a balloon sized 1:1 to the reference size of the vessel, 
(2) optional intravascular ultrasound (IVUS) or OCT 
imaging was recommended for measurement of refer-
ence size and lesion length, (3) selection of scaffold size 
according to invasive measurements or else by visual esti-
mate, (4) implantation of the Fantom BRS to nominal 
pressure, (5) postdilatation with a non-compliant balloon 
with final size not exceeding nominal size +0.5 mm, (6) 
optional evaluation of implantation result by IVUS or 
OCT, (7) documentation of final result by angiography 
and IVUS or OCT (optional). Data describing if and how 
IVUS or OCT scans were used for guiding the implanta-
tion were not collected. Bail-out stenting in case of major 
dissection or occlusive complications at baseline was to be 
performed by implantation of a permanent DES.
Clinical endpoints
Endpoints reported for the OCT substudy population 
includes major adverse cardiac events (MACE) at 6 and 9 
months; a composite of cardiac death, myocardial infarc-
tion and clinically driven target lesion revascularisation; 
the individual components of MACE, all-cause mortality, 
target vessel revascularisation and scaffold thrombosis. 
Endpoints were derived from the main study population 
and by same definitions.8
OCt imaging analysis
All OCT recordings of sufficient quality were analysed. 
Corresponding baseline and follow-up recordings were 
matched on frame level to accommodate for cardiac 
motion artefact and unanalysable scaffold segments (see 
online supplementary file 1). Analysis was performed with 
a sample rate of 0.5 or 0.6 mm to accommodate for differ-
ences in pullback speed. The highly back scattering Fantom 
BRS required an adaptable analysis method implying a 
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Figure 1 OCT appearance and analysis of the Fantom scaffold. (1) OCT image acquisitions showing the unique appearance 
of the Fantom BRS by OCT scan at 6 months. The Fantom BRS was easily distinguished at baseline (A,C) with a highly 
backscattering luminal surface. Due to high attenuation, the abluminal strut surface was not identifiable and analysis was 
performed by applying a customised box delineating the strut with a fixed thickness (Type-R) (C,D,F). At the time of follow-
up, the Fantom BRS remained clearly discernible despite tissue coverage and progressing strut degradation (B,D). Owing 
to the unique appearance of the Fantom BRS by OCT, direct 3D OCT rendering was feasible yielding a well-defined scaffold 
reconstruction without the need for strut segmentation (E). Panel F shows follow-up analysis with lumen contour (red line), strut 
box delineation (white boxes), luminal and abluminal scaffold contours (pink and green lines). BRS, bioresorbable scaffolds; 
OCT, optical coherence tomography.
fixed strut thickness of 125 µm (figure 1). A box was fitted 
to each strut in analysed frames allowing for construction 
of abluminal scaffold contours and detection of possible 
malapposition as distance between the abluminal side 
of the artificial strut box and the lumen contour. OCT 
endpoints were mean lumen area, minimal lumen area, 
mean scaffold area, minimal scaffold area, mean neoin-
timal hyperplasia area, mean neointimal thickness, mean 
extra-stent lumen area, strut malapposition, strut tissue 
coverage, scaffold fracture, discontinued struts and in-scaf-
fold thrombus. Strut tissue coverage was analysed on strut 
level and defined as identifiable tissue fully covering the 
luminal strut surface. Malapposed struts were analysed on 
strut level and defined as struts separated from the luminal 
vessel surface detected as a clear separation of the fitted 
box and the lumen contour abluminal to the strut. Analysis 
for fractured struts at baseline and discontinued struts at 
follow-up was performed at patient level by 3D OCT detec-
tion. Strut fracture and discontinuity were defined as over-
lapping struts in non-overlapping segments, single ended 
strut protrusion of struts into lumen or any abrupt strut 
discontinuity. Thrombus was analysed on patient level and 
defined as any degree of thrombus-material on or attached 
to a strut observed in at least two consecutive frames. 
Derived endpoints at follow-up were lumen area late loss 
(baseline minimal in-scaffold lumen area – follow-up 
minimal in-scaffold lumen area) and mean lumen enlarge-
ment (follow-up mean in-scaffold lumen area – baseline 
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Figure 2 Flowchart of the matched patient population in the FANTOM II Study with a total of 240 patients enrolled at baseline. 
Frame level matched analysis of baseline and follow-up recordings were available in 73 patients in cohort A and 79 patients in 
cohort B. n=patients. OCT, optical coherence tomography.
mean in-scaffold lumen area). OCT analysis was performed 
by the Interventional Coronary Imaging Core Laboratory 
(Aarhus University Hospital, Skejby, Denmark) using the 
QCU-CMS software (Leiden University Medical Center, 
The Netherlands) and QangioOCT RE (Medis medical 
imaging, The Netherlands).
statistical analysis
Categorical variables are reported as mean percentages 
with SD. Continuous variables with a normal distribu-
tion are reported as mean with SD and mean differences 
with 95% CI. Data were analysed on patient level equal-
ling lesion level equalling single study stent level as all 
study patients only had one stent implanted and in one 
lesion. Strut and frame level data were analysed in two 
steps: first on per patient level by simple average and in a 
second step per patient with an over all mean of all obser-
vations. Plots of individual patient’s patient level data are 
provided for main OCT endpoint measures. Continuous 
variables not following normal distribution are reported 
as medians with interquartiles. Testing of matched base-
line and follow-up results on patient level was performed 
with simple paired t-test for normal distributed data and 
non-parametric Wilcoxon signed rank test for data not 
following a normal distribution.
results
Patient population
A total of 240 patients were enrolled in the FANTOM 
II study. The first 117 patients were enrolled in cohort 
A with OCT acquisition performed in 89 patients at 
baseline and in 81 patients at follow-up. The last 123 
patients were enrolled in cohort B with OCT performed 
in 98 patients at baseline and in 94 patients at follow-up 
(online supplementary figure 2). Matched analysis of 
corresponding baseline and follow-up OCT recordings 
was possible for 73 patients in cohort A and 79 patients in 
cohort B (matched population, figure 2). Mean follow-up 
time of the matched cohort was 194 (15) days in cohort A 
and 287 (38) days in cohort B. Patient characteristics are 
presented in table 1 and baseline procedural outcomes 
are presented in table 2.
Clinical outcomes
Clinical events for patients with matched OCT analysis: 
at 6-month follow-up in cohort A, one patient under-
went non-clinically driven target lesion revascularization 
(TLR). Cohort B: Four patients in the matched OCT 
cohort who underwent TLR and OCT from all these 
procedures were included in the matched analysis. In 
patients excluded from the matched OCT cohort due to 
missing follow-up OCT one death, one myocardial infarc-
tion and three TLR were reported. Flowchart for patients 
not included in the matched analysis is shown in online 
supplementary file 1.
OCt imaging results
Qualitative assessment of OCT signature
The Fantom BRS was easily distinguished in both base-
line and 6-month and 9-month follow-up OCT record-
ings exhibiting a highly backscattering luminal surface 
and an abluminal strut border not discernible due to 
high attenuation. Visibility of the Fantom BRS in 3D OCT 
reconstructions by proprietary online tools without the 
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Table 1 Baseline patient characteristics
Baseline data Cohort A (n=73) Cohort B (n=79)
Age (years) 62.7±9.0 62.2±10.6
Male gender 52 (71.2%) 64 (81.0%)
Smoking history 39 (53.4%) 51 (64.6%)
  Current smoker (within the 
past 2 weeks)
15 (20.5%) 16 (20.3%)
Diabetes 12 (16.4%) 22 (27.9%)
Hypertension 53 (72.6%) 54 (68.4%)
Hypercholesterolemia 50 (68.5%) 55 (69.6%)
Family history of CAD 27 (37.0%) 28 (35.4%)
Prior MI 20 (27.4%) 21 (26.6%)
Prior PCI 28 (38.4%) 39 (49.4%)
Patient characteristics for the 73 patients in cohort A and the 79 
patients in cohort B included in the matched OCT analysis. Values 
are n(%) or mean±SD.
CAD, coronary artery disease; MI, myocardial infarction; OCT, 
optical coherence tomography; PCI, percutaneous coronary 
intervention.
Table 2 Baseline lesion and procedural outcomes
Baseline QCA
Cohort A
(n=72*)
Cohort B
(n=79)
Target vessel 
  Left Anterior Decending artery 
(LAD)
37 (51.4%) 41 (51.9%)
  Circumflex artery (Cx) 22 (30.6%) 20 (25.3%)
  Right Coronary Artery (RCA) 13 (18.1%) 18 (22.8%)
ACC/AHA lesion classification 
  Type A 21 (29.2%) 9 (11.4%)
  Type B1 26 (36.1%) 44 (55.7%)
  Type B2 25 (34.7%) 22 (28.8%)
  Type C 0 (0.0%) 4 (5.1%)
Reference vessel diameter (mm) 2.67±0.34 2.74±0.34
Lesion length (mm) 10.8±3.5 12.2±4.3
Procedural data n=73 n=79
Preprocedure antiplatelets 
  Aspirin 73 (100.0%) 79 (100.0%)
  Ticagrelor or clopidogrel 72 (98.6%) 79 (100.0%)
  Other antithrombotic agent 1 (1.4%) 0 (0.0%)
Nominal scaffold diameter (mm) 2.88±0.21 2.89±0.21
Nominal scaffold length (mm) 18.1±0.70 19.0±2.20
Predilatation 73 (100.0%) 79 (100.0%)
Postdilatation 62 (84.9%) 70 (88.6%)
Maximal postdilatation pressure 
(atm)
17±4 17±5
Maximal postdilatation balloon 
diameter (mm)
3.15±0.36 3.26±0.34
Antiplatelets at follow-up 
  Aspirin 73 (100.0%) 78 (98.7%)
  Ticagrelor or clopidogrel 73 (100.0%) 79 (100.0%)
Baseline procedural outcome for patients included in the matched 
analysis. Values are n (%) or mean±SD.
*One preprocedure image was not available for analysis.
QCA, quantitative coronary arteriography.
need for strut detection and segmentation was confirmed 
(figure 1).
Quantitative OCT analysis
Matched analysis of OCT recordings in cohort A (73 
patients) had a total strut count of 40 929 and in cohort 
B (79 patients) the strut count was 46 649. Results are 
presented in table 3. Data analysis revealed a small 
decrease in mean lumen area from 6.8 (1.7) mm2 to 5.7 
(1.4) mm2 in cohort A (p<0.0001) and from 7.2 (1.6) 
mm2 to 5.6 (1.4) mm2 in cohort B (p<0.0001). A similar 
decrease in minimal lumen area was observed in cohort A 
from 5.3 (1.4) mm2 to 4.3 (1.3) mm2 and in cohort B from 
5.7 (1.4) mm2 to 4.1 (1.3) mm2. There was no evidence 
of scaffold area reduction from post-PCI (percutaneous 
coronary intervention) to 6-month or 9-month follow-up 
as mean scaffold area remained stable from 7.1 (1.5) mm2 
to 7.2 (1.4) mm2 (p=0.12) in cohort A and from 7.4 (1.5) 
mm2 to 7.3 (1.4) mm2 in cohort B (p=0.13). Minimal scaf-
fold area was unchanged in cohort A from 5.9 (1.3) mm2 
to 6.0 (1.3) mm2 (p=0.08) and in cohort B from 6.1 (1.4) 
mm2 to 6.1 (1.3) mm2 (p=0.40). Strut level malapposition 
counts were median 0.8 (0.0;3.5)% at baseline in cohorts 
A and 1.8 (0.3;6.0)% in cohort B. In both cohort A and 
cohort B, malapposition was almost resolved at follow-up 
with a median of 0.0 (0.0;0.0)% (figure 3). Tissue 
coverage of struts was complete for 98.1 (95.9;99.4)% of 
struts at 6-month follow-up and 98.9 (98.3;100.0)% at 9 
months (figure 3). Strut fracture at baseline was found 
in seven patients, three in scaffolds exposed to excessive 
expansion and four had subtle discontinuity of a single 
ring or connector without obvious explanation. Strut 
discontinuity at follow-up was seen in four patients at 6 
months including two cases with fracture at baseline. At 
9 months, strut discontinuity was seen in 16 patients of 
whom five were persisting discontinuities and 11 were 
acquired. Importantly, all but one case with fracture or 
late discontinuity had fully apposed struts in the affected 
segments at follow-up and none had clinical events. 
Results of unmatched analysis are presented in online 
supplementary table 1.
dIsCussIOn
The favourable main 6-month and 9-month OCT 
results confirm the previously reported clinical and 
angiographic data. The OCT results indicated that the 
intended performance and healing patterns of the novel 
Fantom BRS achieved: (1) a small but expected decrease 
in mean and minimal lumen area; (2) stable minimal 
scaffold area at follow-up; (3) acute malapposition was 
effectively resolved; (4) no tendency to late vessel wall 
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Table 3 Matched OCT results
Matched OCT results Baseline Follow-up Difference P value
Mean lumen area (mm2) 
  6 months 6.8 (1.7) 5.7 (1.4) 1.1 (−1.3;−0.9) <0.0001
  9 months 7.2 (1.6) 5.6 (1.4) 1.6 (−1.7;−1.4) <0.0001
Minimal lumen area (mm2) 
  6 months 5.3 (1.4) 4.3 (1.3) 1.0 (−1.3;−0.7) <0.0001
  9 months 5.7 (1.4) 4.1 (1.3) 1.6 (−1.9;−1.4) <0.0001
Mean scaffold area (mm2) 
  6 months 7.1 (1.5) 7.2 (1.4) 0.1 (−0.02;0.24) 0.12
  9 months 7.4 (1.5) 7.3 (1.4) −0.1 (−0.19;0.02) 0.12
  9 months 7.4 (1.5) 7.3 (1.4) −0.1 (−0.19;0.02) 0.13
Minimal scaffold area (mm2) 
  6 months 5.9 (1.3) 6.0 (1.3) 0.1 (−0.02;0.25) 0.08
  9 months 6.1 (1.4) 6.1 (1.3) −0.1 (−0.24;0.10) 0.40
Mean extra scaffold lumen area (mm2)* 
  6 months 0.05 (0.02;0.13) 0.00 (0.00;0.02) 0.04 (−0.11;−0.02) <0.0001
  9 months 0.09 (0.04;0.19) 0.00 (0.00;0.02) 0.08 (-1.16;−0.03) <0.0001
Mean neointimal area (mm2)* 
  6 months 1.2 (1.0;1.4)
  9 months 1.4 (1.1;1.7)
Mean neointimal thickness (mm)* 
  6 months 0.057 (0.040;0.077)
  9 months 0.072 (0.056;0.101)
Total analysed struts (N) 
  6 months 20 696 20 233
  9 months 23 775 22 875
Mean strut count per analysis N (SD) 
  6 months 283 (56) 277 (57)
  9 months 301 (62) 290 (62)
Malapposed struts (%)† 
  6 months 0.8 (0.0;3.5) 0.0 (0.0;0.0) −0.7 (−3.5;0) <0.0001
  9 months 1.8 (0.3;6.0) 0.0 (0.0;0.0) −1.5 (−5.1;−0.3) <0.0001
Covered struts (%)† 
  6 months 98.1 (95.9;99.4)
  9 months 98.9 (98.3;100.0)
  Discontinued struts N (%)‡ 2 (2.7) 4 (5.5) 2.7 (−2.4;7.9) 0.16
  6 months 5 (6.3) 16 (20.3) 13.9 (2.9;24.9) 0.01
  9 months 5 (6.3) 16 (20.3) 13.9 (2.9;24.9) 0.01
Thrombus N (%)‡ 
  6 months 48 (65.8) 2 (2.7)
  9 months 43 (54.4) 2 (2.5)
Matched data from the 73 patients in Cohort A and 79 patients in Cohort B. Results are mean (SD).
*Median (interquartile).
†Analysed on strut level, reported as median (IQR).
‡Analysed on patient level.
OCT, optical coherence tomography.
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Figure 3 Healing patterns assessed by OCT. Matched OCT analysis of baseline (A1,B1) and follow-up (A2) recordings 
revealed a slight decrease in mean luminal area after 6 and 9 months as illustrated by the interconnected mean baseline and 
follow-up values (A3,A4) while no evidence of scaffold area reduction was observed (B2,B3). An excellent healing response to 
acute malapposition (C1) with almost completely resolved malapposition at the time of follow-up (C2) even in the few cases of 
major malapposition at baseline (C3,C4). Mean extra-scaffold lumen area at baseline (D1) had also diminished at the time of 
follow-up (D2) even in the few cases of major extra-scaffold lumen area at baseline (D3,D4). A balanced neointimal response 
was observed with a thin layer of tissue covering the struts (E1,E2) in the majority of cases agreeing with the high level of strut 
coverage seen in this study (E3,E4). OCT, optical coherence tomography.
detachment, formation of evaginations or aneurysms and 
(5) strut coverage was almost complete at the 6-month 
and 9-month follow-up.
Introduction of the Absorb BRS was a milestone in 
treatment of obstructive coronary artery disease. The 
positive initial safety reports,9 the restoration of the 
vasomotor function,10 the late lumen enlargement11 
and the full resorption documented after 5 years12 were 
encouraging for the technology. However, recent reports 
on early luminal scaffold dismantling,4 increased rates of 
scaffold thrombosis1 2 and a late increase in target lesion 
failures in comparison with permanent DES2 3 indicates 
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that limitations of first generation BRS affect outcomes 
negatively. Factors related to the BRS design poten-
tially contributing to scaffold failure include the bulky 
struts,13 14 the increased scaffold footprint,15 the limited 
expansion capacity,6 7 limited radial strength,6 16 degra-
dation and embolisation of struts in the lumen due to 
persisting malapposition or late wall detachment of the 
scaffold17 and the poor guidance by angiography.18
In comparison to the Absorb BRS, the Fantom BRS 
was designed with thinner struts to facilitate healing 
and reduce flow disturbance. At the same time, the 
Fantom polymer allowed for maintaining radial strength, 
increased expansion capacity and was radiopaque to 
improve detection of under expansion and scaffold posi-
tion thereby reducing the risk of geographical miss and 
aiding serial implantation of scaffolds.
In the FANTOM II study, we documented that malap-
position was effectively resolved and coverage was almost 
complete at 6 and 9 months. Even in cases with substan-
tial acute malapposition due to underestimation of the 
reference size by the treating physician, malapposi-
tion was effectively reduced. Still, the healing response 
was balanced as indicated by the very few cases with a 
more pronounced reduction in minimal lumen area at 
follow-up. Adverse healing response with development 
of evaginations and aneurysms was a concern with first 
generation DES19 20 and similar healing patterns was 
reported in cases with Absorb BRS.21 With the Fantom 
BRS, we found a substantial reduction in extra stent 
lumen indicating a favourable healing response with only 
two of 152 cases having isolated bulging vessel and no 
cases had generalised patterns of evaginations.
Despite the reduced strut thickness and substantial 
reduction in molecular weight at 6 and 9 months, the 
Fantom BRS maintained stable mean and minimal scaf-
fold area at follow-up and with no late vessel wall detach-
ment. If this important resistance to late recoil continues 
at longer-term follow-up, it may indicate an additional 
differentiating property of the Fantom BRS. The Fantom 
BRS platform allows for expansion beyond the nominal 
size by at least 0.7 mm and safe in vitro expansion up 
to 1.0 mm has been reported by the vendor. By highly 
sensitive 3D OCT analysis, we identified a total of 7/152 
scaffolds with fracture at baseline. Three were caused 
by excessive expansion in attempts to correct malappo-
sition due to severe underestimation of the true vessel 
size, and four had no evident explanation but was 
isolated to a single strut or ring discontinuity. None of 
the patients with fracture at baseline had clinical events. 
Similar findings related to overexpansion were reported 
in ABSORB cohort B which by a less sensitive method 
revealed acute disruption during baseline procedure 
in 2 out of 51 patients (3.9%) possibly related to over 
expansion of the scaffold.4 These findings emphasise 
that despite increased inflation thresholds, meticulous 
sizing is a prerequisite also with the next generation 
BRS. The late acquired strut discontinuity seen in 2.7% 
of cases after 6 months compared with 12% in Absorb 
BRS4 could indicate better structural integrity of Fantom 
BRS at this time point. Some discontinuity at follow-up is 
expected due to resorption and should only be seen as 
problematic if causing lumen reduction or protrusion of 
struts into the lumen. Thrombus elements on struts were 
found in some patients during implantation but not at 
follow-up. This finding did not translate to any clinical 
scaffold thrombosis and, based on the non-comparative 
material it was not possible to determine if the level was 
higher than with regular permanent DES. Still, with the 
present level of evidence, it is encouraged to adhere to 
the mandatory preloading with aspirin and clopidogrel 
or ticagrelor and to maintain dual anti platelet therapy 
for 12 months after implantation.
The FANTOM II study findings indicate that the differ-
entiating design features between the Fantom BRS and 
the Absorb BRS may prove of importance in addressing 
safety concerns raised with first generation BRS. Longer 
term follow-up, studies in more complex lesion subsets 
and adequately powered randomised trials are necessary 
to evaluate if improved structural properties and healing 
patterns of the Fantom BRS translates in to clinical 
outcomes allowing for routine clinical use.
limitations
The FANTOM II study selection criteria only allowed 
enrolment of patients with rather simple lesions limiting 
the assessment of safety and efficacy after implantation 
in complex lesions. Despite the favourable results, the 
single arm design did not allow for a direct compar-
ison of results to established treatments. As with other 
imaging follow-up studies, there could be a bias towards 
the healthy survivors as not all patients were evaluated by 
OCT at baseline and follow-up. By matching the record-
ings, 27 patients with analysable baseline OCT but no 
available follow-up OCT were excluded from analysis. 
Still, unmatched OCT results were remarkably close 
to the matched OCT results and the consequences of 
matching may be considered minimal and outweighed by 
the advantages (online supplementary table 1).
Conclusion
Treatment of coronary stenosis by implantation of the 
Fantom BRS resulted in favourable 6-month and 9-month 
healing patterns as assessed by OCT. Scaffold area 
remained stable, the healing response caused a limited 
lumen reduction, malapposition was effectively resolved 
and strut coverage was almost complete at the 6-month 
and 9-month time points.
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